Diederik J. Höppener

Diederik J. Höppener

Auto-generated profile, based on publicly available information

Diederik J. Höppener

1)Department of Surgery, Erasmus MC Cancer Institute, Erasmus University, Rotterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2022 in European Journal of Cancer
Verified
Journal Article
Open access
FBFlorian E. Buisman
Florian E. Buisman
DGDaniele Giardiello
Daniele Giardiello
NKNancy E. Kemeny
Nancy E. Kemeny
ESEwout W. Steyerberg
Ewout W. Steyerberg
DHDiederik J. Höppener
Diederik J. Höppener
BKBas Groot Koerkamp
Bas Groot Koerkamp
The aim of this study was to develop a prediction model for 10-year overall survival (OS) after resection of colorectal liver metastasis (CRLM) based on patient, tumor, and treatment characteristics. Consecutive patients after complete resection of CRLM were included from two centers (1992–2019). A prediction model providing 10-year OS probabilities was developed using Cox regression analysis including KRAS, BRAF, and histopathological growth patterns. Discrimination and calibration were assessed using cross-validation. A web-based calculator was built to predict individual 10-year OS probabilities. A total of 4112 patients were included. The estimated 10-year OS was 30% (95% CI 29–32). Fifteen patient, tumor, and treatment characteristics were independent prognostic factors for 10-year OS; age, gender, location and nodal status of the primary tumor, disease-free interval, number and diameter of CRLM, preoperative CEA, resection margin, extrahepatic disease, KRAS and BRAF mutation status, histopathological growth patterns, perioperative systemic chemotherapy, and hepatic arterial infusion pump chemotherapy. The discrimination at 10-years was 0.73 for both centers. A simplified risk score identified four risk groups with a 10-year OS of 57%, 38%, 24%, and 12%. Ten-year OS after resection of CRLM is best predicted with a model including 15 patient, tumor, and treatment characteristics. The web-based calculator can be used to inform patients. This model serves as a benchmark to determine the prognostic value of novel biomarkers.

4 September 2021 in The Journal of Pathology: Clinical Research
Verified
Journal Article
Open access
PDF file
PNPieter Mh Nierop
Pieter Mh Nierop
DHDiederik J Höppener
Diederik J Höppener
FBFlorian E Buisman
Florian E Buisman
ESEric P van der Stok
Eric P van der Stok
BGBoris Galjart
Boris Galjart
Cornelis VerhoefCornelis Verhoef
Cornelis Verhoef
Histopathological growth patterns (HGPs) are a reliable, reproducible, and strong prognostic biomarker that can be assessed on haematoxylin and eosin‐stained sections of resected colorectal liver metastases (CRLM). Assessment estimates the relative fraction of the tumour–liver interface for each of the three growth patterns; the desmoplastic HGP reflects good prognosis. Whether preoperative chemotherapy affects the HGP is currently unclear. The present international multicentre study evaluates this in an original cohort of 877 consecutive patients treated in the Netherlands, an external validation cohort of 1,203 consecutive patients treated in the USA, and a post hoc analysis from the phase III randomised controlled European Organization for Research and Treatment of Cancer (EORTC) 40983 trial (n = 70). All patients underwent resection of CRLM with or without preoperative systemic chemotherapy. Trial patients were randomised between perioperative chemotherapy and resection or resection alone. HGPs were determined according to consensus guidelines and compared for preoperative treatment status. Data from three separate tumour regression grading systems were available for the trial cohort. These were correlated with HGP stratified for treatment arm. In the original cohort, the average presence of desmoplastic HGP was 43% for chemo‐naïve versus 67% for preoperatively treated patients (p < 0.001). A significant association between chemotherapy and desmoplastic HGP was found on multivariable analysis (β [95% confidence interval, CI]: 24.57 [18.28–30.87], p < 0.001). In the validation cohort, the average presence of desmoplastic HGP was 40% for chemo‐naïve versus 63% for preoperatively treated patients (p < 0.001). This association remained on multivariable analysis (β [95% CI]: 24.18 [18.70–29.66], p < 0.001). In the EORTC 40983 trial, the average desmoplastic HGP presence was 33% in the resection arm versus 61% in the chemotherapy arm (p = 0.005). Chemotherapy was independently associated with an increase in desmoplastic HGP (β [95% CI]: 23.29 [1.78–44.79], p = 0.022). All three tumour regression gradings were significantly associated with the desmoplastic HGP in the chemotherapy arm (all p < 0.04). None were associated in the resection arm (all p > 0.11). Preoperative chemotherapy induces histopathological changes that alter the HGP of CRLM.

1 April 2022 in HPB
Verified
Journal Article
Closed access
YMYannick M. Meyer
Yannick M. Meyer
BBBerend Beumer
Berend Beumer
DHDiederik J. Höppener
Diederik J. Höppener
PNPieter M.H. Nierop
Pieter M.H. Nierop
MDMichail Doukas
Michail Doukas
Jan IJzermansJan IJzermans
Jan IJzermans

1 February 2019 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
MNM. Nierop
M. Nierop
BGB. Galjart
B. Galjart
DHD. Höppener
D. Höppener
ESE. van der Stok
E. van der Stok
RBR. Coebergh van Den Braak
R. Coebergh van Den Braak
Cornelis VerhoefCornelis Verhoef
Cornelis Verhoef

1 February 2020 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
DHDiederik Höppener
Diederik Höppener
PNPieter Nierop
Pieter Nierop
JHJoost Hof
Joost Hof
KSKostas Sideras
Kostas Sideras
GZGuoying Zhou
Guoying Zhou
Cornelis VerhoefCornelis Verhoef
Cornelis Verhoef